Davis Polk advised the representatives of the several underwriters, in connection with an SEC-registered offering by Nevro Corp. of $172.5 million aggregate principal amount of its 1.75% convertible senior notes due 2021. In addition, Davis Polk advised the counterparties to convertible note hedge and warrant transactions in connection with the convertible notes offering.

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro’s proprietary HF10 therapy.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Marcus K. Hintze and Dongbiao Shen. The derivatives team included partner Mark M. Mendez and associates Mark J. DiFiore and Mo Zhou. Partner Rachel D. Kleinberg and associate Elina Khodorkovsky provided tax advice. Associates Michelle Gross and Jason J. Bang provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post